CULVER CITY, Calif.--(BUSINESS WIRE)--
NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based,
personalized healthcare company, today announced that it has been
selected by NASDAQ for inclusion in the NASDAQ Biotechnology Index®
(NASDAQ: NBI). The annual re-ranking of the NASDAQ Biotechnology Index
will become effective at market open on
Monday, December 19, 2016.
The Index is designed to track the performance of a set of securities
listed on The Nasdaq Stock Market® (NASDAQ®) that
are classified as either biotechnology or pharmaceutical according to
the Industry Classification Benchmark (ICB).
“We are pleased with the addition of NantHealth to the NBI,” said
Patrick Soon-Shiong, M.D., chief executive officer and chairman of
NantHealth. “Inclusion in the NBI will enable exposure of NantHealth to
a broader range of investors.”
About NantHealth
NantHealth is a transformational healthcare IT company converging
science and technology through a single integrated clinical platform, to
provide actionable health information at the point of care, in the time
of need, anywhere, anytime. NantHealth works to transform clinical
delivery with actionable clinical intelligence at the moment of
decision, enabling clinical discovery through real-time machine learning
systems. The company’s technology empowers physicians, patients, payers
and researchers to transcend genomics into the world of proteomics and
the traditional barriers of today’s healthcare system. By converging
molecular science, computer science and big data technology, the Nant
Service Oriented Operating System (NantOS) platform empowers physicians,
patients and payers to coordinate best care, monitor outcomes and
control cost in real time. This is the first operating system of its
kind in healthcare that is based on supply chain principles and grid
service oriented architecture and integrates the knowledge base with the
delivery system and the payment system, enabling 21st century
coordinated care at a lower cost. For more information, please visit www.nanthealth.com
and follow Dr. Soon-Shiong on Twitter @solvehealthcare.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161213005523/en/
for NantHealth
Investor Contact:
Robert Jaffe, 424-288-4098
rjaffe@rjaffeco.com
Source: NantHealth
